No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker GSK said on Wednesday that China's National Medical Products Administration has approved Exdensur as an addon therapy with intranasal corticosteroids for adults with chronic rhinosinusitis with nasal polyps who do not achieve adequate control with systemic steroids or surgery.
GSK noted that the NMPA's decision follows its recent approval of Exdensur as an addon maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 and over.
The FTSE 100-listed gruop said the regulator's approval was supported by data from its recent phase III ANCHOR1 and ANCHOR2 trials, which showed reductions in nasal polyp score at 52 weeks and improvements in nasal obstruction scores over weeks 49-52. Across both studies, Exdensur was generally welltolerated, with sideeffect rates similar to placebo plus standard care.
GSK's Kaivan Khavandi said: "Given the continued unmet need amongst patients with CRSwNP, today's approval of Exdensur could redefine care by protecting from the debilitating symptoms of this disease in just two doses a year. This builds on Exdensur's recent approval in severe asthma, which means more patients in China could have access to this first and only ultra-long-acting biologic."
As of 0930 BST, GSK shares were up 1.81% at 2,134p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS at Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.